Investigation of new ARB effect on the function of EPCs

Investigation of new ARB effect on the function of EPCs - Effect of new ARB on EPCs

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009484

Enrollment

Registered

2012-12-05

Start date

2012-09-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive type two diabetes

Interventions

New ARB aglisaltan treated group Non ARB aglisaltan treated group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) systolic pressure more than 14mmHg and below 160mmHg 2) Type 2 diabetes

Exclusion criteria

Exclusion criteria: 1) Patient already treated with ARB or ACE blockers 2)Patients with diabetic nephropathy 3)allergic to azirsartan 4) patients with pregnancy 5) others who physician incharge thought was inappropriate

Design outcomes

Primary

Measure	Time frame
EPC vasculogenic function by EPC colony forming assay	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026